ClinicalTrials.gg
Not yet recruitingNCT06835179Updated Feb 19, 2025

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

A Phase 2 interventional study of SBRT and PD-1 Inhibitors in Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC) and RAS-mutant Colorectal Cancer, sponsored by The First Affiliated Hospital with Nanjing Medical University. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing Immune checkpoint inhibitors in Spinocerebellar Degenerations — 5 open to participants now, 5 under way, 2 of them phase 3. A drug class: Immune checkpoint inhibitors · Spinocerebellar Degenerations.

Planned enrollment
10th of 12
28 · median 80
Started
2025
with 1 other
Phase 2
7 of 12
3 open now
Registered
8th of 12
by date
Lead sponsor
1 of 12
The First Affiliated Hospital with Nanjing Medical University

Among the 12 studies testing Immune checkpoint inhibitors in Spinocerebellar Degenerations, this one is the 10th largest by planned enrollment, is one of 2 that started in 2025, is one of 7 in phase 2, and was the 8th registered.

Spinocerebellar Degenerations

49 studies on the registry are indexed under Spinocerebellar Degenerations; 15 are open to participants now.

Browse Spinocerebellar Degenerations studies →

Open to participants now

5 of the 12 studies testing Immune checkpoint inhibitors in Spinocerebellar Degenerations are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Immune checkpoint inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 9 Spinocerebellar Degenerations studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Immune checkpoint inhibitors in Spinocerebellar Degenerations, or all of them as a file.
02

Study summary

SBRT Combined with CAPEOX, Bevacizumab, and PD-1 Inhibitor in RAS-Mutant, Microsatellite Stable (MSS), Unresectable Metastatic Colorectal Cancer (mCRC): a Single-center, Single-arm, Open-label Clinical Trail

Read the detailed description

Colorectal cancer (CRC) is currently one of the most common malignant tumors of the digestive tract in clinical practice. According to the latest cancer data in China, CRC ranks as the fourth leading cause of cancer-related deaths, with both its incidence and mortality rates showing an increasing trend. The early diagnosis and treatment rates of CRC in China remain significantly lower compared to developed countries. Most patients are diagnosed at locally advanced or metastatic stages, resulting in poor treatment outcomes and prognosis. Among newly diagnosed cases, 20% already present with distant metastases (metastatic colorectal cancer, mCRC), with a 5-year survival rate below 20%.

The NCCN and CSCO guidelines recommend standard treatments for mCRC patients, including fluorouracil-, oxaliplatin-, and/or irinotecan-based chemotherapy regimens combined with angiogenesis-targeting agents (e.g., bevacizumab) or epidermal growth factor receptor (EGFR)-targeted therapies (e.g., cetuximab), depending on the patient's RAS and BRAF status. RAS mutations are present in 50-56% of mCRC cases. For RAS-mutant mCRC patients, bevacizumab combined with chemotherapy is the standard first-line treatment. However, these patients exhibit poorer prognoses and shorter survival times compared to those with RAS wild-type mCRC. Studies also indicate that RAS-mutant mCRC features an immunosuppressive tumor microenvironment. Thus, enhancing the efficacy of first-line therapy for this subgroup remains a major clinical challenge.

In recent years, immune checkpoint inhibitors (ICIs) have revolutionized treatment paradigms for several solid cancers, including melanoma and lung cancer, by inducing durable responses and significantly improving outcomes. Microsatellite instability-high (MSI-H) CRC, characterized by high tumor mutational burden and neoantigen production, activates the immune system and demonstrates high responsiveness to ICIs. Multiple immunotherapies have been approved for MSI-H CRC, markedly prolonging survival and improving quality of life. However, microsatellite stable (MSS) mCRC, accounting for approximately 95% of cases, is considered an immunologically "cold tumor" due to low tumor mutational burden and limited immune cell infiltration. Only a small subset of MSS patients, such as those with POLE/POLD1 mutations, may benefit from ICIs, whereas monotherapy with ICIs shows minimal efficacy in most MSS/pMMR tumors. Consequently, novel strategies are urgently needed to enhance immunotherapy responses in this subgroup.

Radiotherapy not only improves local tumor control by directly killing irradiated tumor cells but also activates systemic antitumor immunity through multiple mechanisms, potentially reducing metastatic risk and synergizing with immunotherapy. First, radiotherapy promotes the release of pro-phagocytic signals (e.g., calreticulin) while downregulating anti-phagocytic signals like CD47, enhancing macrophage-mediated tumor phagocytosis. Post-radiotherapy release of high-mobility group box 1 (HMGB1) and upregulation of MHC-I expression facilitate tumor antigen processing and presentation to CD8+ T cells. Additionally, radiation-induced DNA damage may generate neoantigens and trigger immune surveillance. Studies show that DNA repair-deficient tumor cells exhibit growth suppression in immunocompetent mice post-radiotherapy, a phenomenon absent in immunodeficient models, suggesting that accumulated mutations in repair-deficient cells increase neoantigen burden and drive immune responses. Radiation may also elevate mutational load, providing novel targets for immune recognition. Furthermore, radiotherapy modifies the tumor stromal microenvironment by inducing cytokine production. For instance, radiation promotes TNF release, significantly reducing myeloid-derived suppressor cell (MDSC) infiltration, while enhancing CXCL9/CXCL10 secretion to recruit cytotoxic T cells. Collectively, these mechanisms shift the immune milieu toward tumor elimination, providing a rationale for combining radiotherapy with immunotherapy.

Against this backdrop, we designed this study: Evaluation of the Efficacy and Safety of SBRT Combined with CAPEOX, Bevacizumab, and PD-1 Inhibitor in RAS-Mutant, Microsatellite Stable (MSS), and Unresectable Metastatic Colorectal Cancer (mCRC) : a Single-center, Single-arm, Open-label Clinical Trail.

03

Conditions studied

  • Unresectable Metastatic Colorectal Cancer
  • Microsatellite Stable (MSS) Colorectal Cancer (CRC)
  • RAS-mutant Colorectal Cancer

Keywords

  • SBRT
  • CAPEOX
  • Bevacizumab
  • PD-1 Inhibitor
  • RAS-Mutant
  • Microsatellite Stable (MSS)
  • Unresectable Metastatic Colorectal Cancer (mCRC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-75 years, regardless of gender.
  • Lower edge of the lesion located ≥12 cm from the anal verge.
  • confirmed colorectal adenocarcinoma.
  • Confirmed as unresectable by multidisciplinary team (MDT) evaluation.
  • RAS mutation-positive.
  • Microsatellite/mismatch repair status: MSS/pMMR.
  • (ECOG) performance status of 0 or 1.
  • Expected survival ≥3 months.
  • Adequate hematological, hepatic, and renal function:

≥1.5 × 10⁹/L; count ≥75 × 10⁹/L; Serum total ≤1.5 × upper normal limit (UNL); (AST) ≤2.5 × UNL; Alanine aminotransferase (ALT) ≤2.5 × UNL; Serum creatinine ≤1.5 × UNL.

  • Performance Status (KPS) score ≥70.
  • Adequate organ function with no to surgery, radiotherapy, chemotherapy, or immunotherapy.
  • No prior chemotherapy or other antitumor therapy before enrollment.
  • No prior immunotherapy received.
  • Willingness and ability to comply with the study protocol during the trial period.
  • Signed written .

Exclusion criteria

Exclusion Criteria:

  • Patients who have received antibodies against programmed death receptor-1 () or its ligand (PD-L1), as well as antibodies against cytotoxic T lymphocyte associated antigen 4 (CTLA-4).
  • Patients with any active diseases or a history of requiring or immunotherapy treatment.
  • Complex situations with concurrent active bleeding, perforation, or requiring emergency surgery.
  • Have received systemic anti-cancer treatment for rectal cancer.
  • Simultaneously present with other non colorectal cancer tumor diseases.
  • Patients with interstitial lung disease, non infectious pneumonia or uncontrollable systemic diseases (such as diabetes, hypertension, pulmonary fibrosis and acute pneumonia).
  • Any grade 2 or above toxic reactions (classified according to the (CTCAE) 5th edition) caused by previous treatment that have not subsided (excluding anemia, hair loss, and skin pigmentation).
  • Pregnant or lactating women.
  • Patients who are known or have been tested for (HIV) or acquired immunodeficiency syndrome (AIDS).
  • Known or suspected history of allergies to any relevant drugs used in the trial
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Patients first receive short-course SBRT (total dose of 30-60 Gy, completed in 3-5 fractions). Within two weeks after SBRT, the liver function and other toxicity reactions of patients are closely monitored to ensure they can tolerate subsequent drug treatment. Then, patients proceed to drug therapy: each treatment cycle lasts for 21 days, including intravenous administration of tislelizumab (200mg on day 1), bevacizumab (7.5mg/kg on day 1), oxaliplatin (135mg/m² on day 1), as well as oral capecitabine (1g/m² twice daily from day 1 to day 14). Up to six cycles of induction therapy may be administered

    Radiation: SBRT · Drug: PD-1 Inhibitors · Drug: CapeOX + bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR rate)

    ORR is defined as the proportion of patients who achieve the best objective response, either complete response (CR) or partial response (PR), according to the RECIST criteria (version 1.1).

    Time frame: 1 year

Secondary outcomes

  1. Disease Control Rate (DCR)

    DCR is defined as the proportion of patients who achieve complete response (CR), partial response (PR), or disease stability (SD) according to the RECIST criteria (version 1.1).

    Time frame: 1 year

  2. Progression Free Survival (PFS)

    PFS is defined as the time from enrollment to the first recording of disease progression, or the time of death from any cause, whichever occurs earlier.

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2025; primary completion for Feb 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Feb 19, 2025
StartEst.
Feb 2025
Primary completionEst.
Feb 2027
CompletionEst.
May 2027
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06835179
Responsible party
Sponsor
First posted
Feb 19, 2025
Start date
Feb 2025 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Feb 19, 2025

Study contacts

Yueming Sun
Contact
sunyueming@njmu.edu.cn
025-68306026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Immune checkpoint inhibitors · Xelox · Bevacizumab

Start the discussion